Two research teams have shown that stromal cells produce an expression profile associated with poor-prognosis forms of colorectal cancer.
The proof-of-principle application suggests networks of microRNA, RNA, and other 'omics data can untangle drug response and more.
Researchers have developed a tool called RNA-Rocket to link RNA-seq and ChIP-seq software with data from pathogen-related sequence databases.
Transposons with binding sites for the progesterone receptor lent nearby genes the ability to be regulated by the hormone, providing a mechanism to evolve a new trait.
The algorithm could help detect potential circular RNAs for scientists to validate, opening up the poorly characterized genomic products for further study.
The study demonstrated that the company's DecisionDx-Melanoma assay better predicts the risk of metastasis in patients with localized disease than clinical staging alone.
The test, which indicates risk of heart transplant rejection, is now available to patients in 11 additional states.
Using antibody affinity bead-based capture and Illumina's Whole Genome-DASL HT, the group could accurately collect gene expression profiles of tumor cells in blood.
Several regulatory genes are responsible for starting a process that both kills surrounding bacteria and adds their DNA to the pathogen's own genome.
The partners will work together to commercialize findings about the genetic basis of pain sensitivity and individual response to commonly prescribed pain medicines.
The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.
60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.
In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.
GenomeWeb reports that Veritas Genetics is suspending its US operations.